MONTREAL, QC -Canadian specialty pharmaceutical company Knight Therapeutics Inc. has commercially relaunched MOVANTIK, a peripherally-selective opioid antagonist, in Canada.
The drug, which comes in tablet form, is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with non-cancer pain who have had an inadequate response to laxatives. According to the Canadian Family Physician Practice Guideline, it is estimated that at least 26 per cent of chronic opioid users suffer from OIC.
MOVANTIK acts primarily on mu-opioid receptors in the gut and counteracts OIC with limited impact on opioid-mediated analgesic effects on the central nervous system at the intended therapeutic doses.
“MOVANTIK represents our first commercial specialty product in Canada,” said Jonathan Ross Goodman, CEO of Knight Therapeutics Inc. “MOVANTIK’s targeted mechanism of action offers an additional therapeutic option for healthcare professionals managing patients with OIC and it fits seamlesly with Knight’s portfolio of pain supportive therapeutics.”
Knight obtained the exclusive license to market and sell MOVANTIK in Canada and Israel from AstraZeneca in December 2016.